Esketamine - Johnson & Johnson
Alternative Names: Esketamine nasal spray; JNJ-54135419; JNJ-54135419-AAA; JNJ-5419; S-ketamine; SPRAVATOLatest Information Update: 18 Nov 2025
At a glance
- Originator Johnson & Johnson
- Class Analgesics; Antidepressants; Chlorobenzenes; Cyclohexanones; General anaesthetics; Small molecules
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Major depressive disorder
Most Recent Events
- 12 Nov 2025 Janssen Research & Development plans the phase III AVENUE trial for Major depressive disorder (In adolescents, Adjunctive treatment) (Intranasal), in November 2025 , (NCT07227454)
- 21 Jan 2025 Registered for Major depressive disorder (Monotherapy, Treatment-resistant) in USA (Intranasal)
- 22 Jul 2024 Preregistration for Major depressive disorder (Treatment-resistant, Monotherapy) in USA (Intranasal)